Clinical Trials Logo

Lymphoma, Extranodal NK-T-Cell clinical trials

View clinical trials related to Lymphoma, Extranodal NK-T-Cell.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT04602065 Terminated - Clinical trials for Extranodal NK/T Cell Lymphoma, Nasal Type

Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) Trial

Start date: November 24, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of IBI318 monotherapy for relapsed/refractory extranodal NK/T cell lymphoma (nasal type).

NCT ID: NCT04509466 Terminated - Clinical trials for Extranodal NK/T-cell Lymphoma, Nasal Type

Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL

Start date: September 15, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicentre, open-label, single-arm, phase I/II clinical study to evaluate the safety, efficacy and pharmacokinetics of liposomal mitoxantrone hydrochloride in combination with pegaspargase in patients with extranodal natural killer/T-cell lymphoma, nasal type (NKTCL).

NCT ID: NCT03075553 Terminated - Clinical trials for Recurrent Adult T-Cell Leukemia/Lymphoma

Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Start date: May 17, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well nivolumab works in treating patients with peripheral T-cell lymphoma that has come back after a period of improvement or that does not respond to treatment. Monoclonal antibodies, such as nivolumab, may block cancer growth in different ways by targeting certain cells.

NCT ID: NCT02808091 Terminated - Clinical trials for Extranodal NK-T-CELL LYMPHOMA

Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell Lymphoma

Gifox-B
Start date: March 2011
Phase: Phase 2
Study type: Interventional

- Assess responses, progression free survival (PFS) and overall survival (OS) of the combination of GIFOX-B chemotherapy with intensity-modulated radiation therapy (IMRT) in Stage IB or bulky disease - II and without IMRT in Stage III - IV. - Assess the toxicity and maximum tolerated dose of bortezomib administered in combination with GIFOX chemotherapy.

NCT ID: NCT02533323 Terminated - Clinical trials for Lymphoma, Extranodal NK-T-Cell

P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens

Start date: January 2012
Phase: Phase 2
Study type: Interventional

This prospective study was conducted to evaluate the efficacy and safety profiles of first-line combined gemcitabine, oxaliplatin, and Pegaspargase (P-Gemox) in newly diagnosed, nasal type, extranodal natural killer/T-cell lymphoma.

NCT ID: NCT02359162 Terminated - Clinical trials for Lymphoma, Extranodal NK-T-Cell

Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage

Start date: May 2015
Phase: Phase 3
Study type: Interventional

Purpose :To compare the efficacy and and safety of the P-Gemox chemotherapy regimen with those of the EPOCH regimen for stage IE to IIE ENKTL.

NCT ID: NCT02168907 Terminated - Clinical trials for Recurrent Mantle Cell Lymphoma

CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Start date: December 2014
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of CPI-613 (6,8-bis[benzylthio]octanoic acid) when given together with bendamustine hydrochloride and rituximab in treating patients with B-cell non-Hodgkin lymphoma that has come back or has not responded to treatment. Drugs used in chemotherapy, such as 6,8-bis(benzylthio)octanoic acid and bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as rituximab, may find cancer cells and help kill them. Giving 6,8-bis(benzylthio)octanoic acid with bendamustine hydrochloride and rituximab may kill more cancer cells.

NCT ID: NCT02109224 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection

Start date: September 2014
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of ibrutinib in treating B-cell non-Hodgkin lymphoma that has returned or does not respond to treatment in patients with human immunodeficiency virus (HIV) infection. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether it is safe for patients with HIV infection to receive ibrutinib while also taking anti-HIV drugs.

NCT ID: NCT01948180 Terminated - EBV Clinical Trials

Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma

CITADEL
Start date: September 2014
Phase: Phase 2
Study type: Interventional

To investigate the efficacy of autologous EBV-specific T-cells for the treatment of patients with aggressive EBV positive extranodal NK/T-cell lymphoma

NCT ID: NCT01805037 Terminated - Clinical trials for Recurrent Mantle Cell Lymphoma

Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas

Start date: March 5, 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate how safe and effective the combination of two different drugs (brentuximab vedotin and rituximab) is in patients with certain types of lymphoma. This study is for patients who have a type of lymphoma that expresses a tumor marker called CD30 and/or a type that is associated with the Epstein-Barr virus (EBV-related lymphoma) and who have not yet received any treatment for their cancer, except for dose-reduction or discontinuation (stoppage) of medications used to prevent rejection of transplanted organs (for those patients who have undergone transplantation). This study is investigating the combination of brentuximab vedotin and rituximab as a first treatment for lymphoma patients